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SocietyLetter to the Editor
Response to Letter to Editor entitled: ‘‘Avocado/soybean unsaponﬁables,
ASU Expanscience, are strictly different from the nutraceutical
products claiming ASU appellation’’ (4365)In their letter to the editor, Msika et al. alleged that Labora-
tories Expanscience (‘‘Expanscience’’) has the only avo-
cado/soybean unsaponiﬁable (ASU) product, Piascledine
that contains a mixture of soybean unsaponiﬁables and
speciﬁc avocado unsaponiﬁables. ‘‘ASUs are deﬁned as
the fraction of avocado and soybean oil which, after hydro-
lysis is not producing soap’’1. Nutramax Laboratories, Inc.
(‘‘Nutramax’’) products, Dasuquin and Avoca ASU also
contain ASU. This virulent response to our paper reﬂects
their deep concern that NMX1000 ASUs from Nutramax
may be a strong competitor entering into the ASU market-
place. The Expanscience authors even went through the
process of procuring some of Nutramax products that con-
tain ASU for testing. We are ﬂattered that the authors have
gone to all this effort to assay our veterinary product Dasu-
quin and our health food product Avoca ASU both of
which contain ASU, merely to point out that some compo-
nent levels of their ASU mixture are different from Nutramax
products. Although Expanscience has pioneered the accep-
tance of ASU as an ingredient for joint health in Europe, the
authors made unsubstantiated comments that need to be
refuted.
Msika et al. contended that the active principle of Piascle-
dine can be attributed to certain ‘‘speciﬁc’’ constituents of
their ASU material marketed by Expanscience including cit-
rostadienol (avocado unsaponiﬁable imprint) listed in Table 1
of their article. They further asserted that citrostadienol was
missing from Nutramax products that contain ASU. A major
problem with this assertion is that the test methods used
by Msika et al. are not validated for assessment of Nutramax
ﬁnished products that contain ASU. There is no basis to
suggest that their methodology is reliable or appropriate for
comparing the Expanscience ASU product with Nutramax
products that contain ASU. Moreover, Msika et al. are incor-
rect in suggesting that citrostadienol is only found in avocado
extract. Rather, citrostadienol is found in soybean oil, rice
bran, olive oil, berries and other oils conﬁrming that this mol-
ecule is not a speciﬁcmarker selectively found in avocado2,3.
They also pointed to detectable levels of brassicasterol
found in Nutramax products but not in Piascledine. Brassi-
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1590extracts and avocado4,5. They stated that Piascledine con-
tains greater levels of tocopherols. However, research spon-
sored by Expanscience itself conﬁrms that it is unclear which
component(s) in ASU is(are) effective6e8. Moreover, the ar-
gument by Msika et al. that the ASU ratio of 1:2 is the only
effective ratio is questionable based on research reported
by their own scientists which shows that other ASU mix-
tures/residues elicit an effect9.
Msika et al. also alleged that Expanscience’s Piascledine
has some unique ASU components in its formulation which
may be due to its patentedmanufacturing process. However,
to date, it is not known what ASU component or more likely
set of components is responsible for the observed biological
effects of various ASU products. Lippiello et al. have
evaluated ASU materials from Expanscience and other
ASU sources using gas chromatography mass spectrometry
(GC-MS) and reported some variability in components from
the different ASU sources10. These differences, however,
do not alter the ﬁnding that all the different ASU materials
tested were found to be effective in vitro. Moreover, head
to head comparison has shown that NMX1000 and Piascle-
dine elicit similar responses from tissue cells in vitro10.
In conclusion, our publication documents the in vitro
response of tissue cells to NMX1000 which shows an effect
on several markers of joint pain11. In certain countries, ASU
is characterized as a pharmaceutical agent and in some Eu-
ropean countries as well as the United States of America as
a nutritional supplement. The quality of some nutritional
supplements can vary and most supplement companies
do not study their products. Our study using NMX1000
described in Osteoarthritis and Cartilage is the ﬁrst of
several investigations to further the scientiﬁc understanding
and value of ASU. We have presented several abstracts
( podium and posters) describing the effects of NMX1000
within the past several months which are being submitted
for publication12e17.
In our view, Expanscience’s letter to the editor is the
response of a competitor seeking to prolong its market
share by unfairly criticizing new products that have shown
a positive response and growing acceptance among health
professionals and consumers.Conﬂict of interest
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